OFI Invest Asset Management Makes New $25.12 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

OFI Invest Asset Management bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 281,622 shares of the biopharmaceutical company’s stock, valued at approximately $25,122,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC grew its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 293,356 shares of company stock worth $29,166,240. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.24.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $117.41 on Friday. The company’s 50 day simple moving average is $99.61 and its 200 day simple moving average is $91.50. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $118.42. The stock has a market capitalization of $146.22 billion, a price-to-earnings ratio of 317.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.69%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.